Brief: Inhibikase Therapeutics Announces FDA Clearance Of Investigational New Drug Application For Ikt-001Pro
26/08/2022 14:09
Aug 26 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS ANNOUNCES FDA CLEARANCE OF
INVESTIGATIONAL NEW DRUG APPLICATION FOR IKT-001PRO FOR THE
TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA
* INHIBIKASE THERAPEUTICS INC - LOOK FORWARD TO INITIATING A
BIOEQUIVALENCE STUDY FOR IKT-001PRO IN SECOND HALF OF 2022
Source text for Eikon: ID:nPnbXhLlJa
Further company coverage: IKT.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Appoints Scott Wasserman To Board Of Directors
Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Inhibikase Q2 net loss widens on higher R&D, SG&A costs
Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share